229 related articles for article (PubMed ID: 33968977)
1. SphK2/S1P Promotes Metastasis of Triple-Negative Breast Cancer Through the PAK1/LIMK1/Cofilin1 Signaling Pathway.
Shi W; Ma D; Cao Y; Hu L; Liu S; Yan D; Zhang S; Zhang G; Wang Z; Wu J; Jiang C
Front Mol Biosci; 2021; 8():598218. PubMed ID: 33968977
[TBL] [Abstract][Full Text] [Related]
2. Regulation of hypoxia-inducible factor functions in the nucleus by sphingosine-1-phosphate.
Hait NC; Maiti A; Xu P; Qi Q; Kawaguchi T; Okano M; Takabe K; Yan L; Luo C
FASEB J; 2020 Mar; 34(3):4293-4310. PubMed ID: 32017264
[TBL] [Abstract][Full Text] [Related]
3. Targeting SphK2 Reverses Acquired Resistance of Regorafenib in Hepatocellular Carcinoma.
Shi W; Zhang S; Ma D; Yan D; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Front Oncol; 2020; 10():694. PubMed ID: 32670862
[No Abstract] [Full Text] [Related]
4. Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Wang S; Liang Y; Chang W; Hu B; Zhang Y
Med Sci Monit; 2018 Apr; 24():1912-1923. PubMed ID: 29605826
[TBL] [Abstract][Full Text] [Related]
5. Metastatic triple-negative breast cancer is dependent on SphKs/S1P signaling for growth and survival.
Maiti A; Takabe K; Hait NC
Cell Signal; 2017 Apr; 32():85-92. PubMed ID: 28108260
[TBL] [Abstract][Full Text] [Related]
6. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
[TBL] [Abstract][Full Text] [Related]
7. Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis.
Baker DA; Eudaly J; Smith CD; Obeid LM; Gilkeson GS
Rheumatol Int; 2013 Oct; 33(10):2677-81. PubMed ID: 23011090
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor.
Guan S; Liu YY; Yan T; Zhou J
Biochem Biophys Res Commun; 2016 Aug; 476(4):230-236. PubMed ID: 27221045
[TBL] [Abstract][Full Text] [Related]
9. DEP Domain-Containing Protein 1B (DEPDC1B) Promotes Migration and Invasion in Pancreatic Cancer Through the Rac1/PAK1-LIMK1-Cofilin1 Signaling Pathway.
Zhang S; Shi W; Hu W; Ma D; Yan D; Yu K; Zhang G; Cao Y; Wu J; Jiang C; Wang Z
Onco Targets Ther; 2020; 13():1481-1496. PubMed ID: 32110046
[TBL] [Abstract][Full Text] [Related]
10. Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
Xun C; Chen MB; Qi L; Tie-Ning Z; Peng X; Ning L; Zhi-Xiao C; Li-Wei W
J Exp Clin Cancer Res; 2015 Sep; 34(1):94. PubMed ID: 26337959
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine kinase 2 and sphingosine-1-phosphate promotes mitochondrial function in dopaminergic neurons of mouse model of Parkinson's disease and in MPP+ -treated MN9D cells in vitro.
Sivasubramanian M; Kanagaraj N; Dheen ST; Tay SS
Neuroscience; 2015 Apr; 290():636-48. PubMed ID: 25637806
[TBL] [Abstract][Full Text] [Related]
12. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth.
Zhou J; Chen J; Yu H
Biochem Biophys Res Commun; 2018 Mar; 497(2):535-542. PubMed ID: 29428730
[TBL] [Abstract][Full Text] [Related]
13. Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
Antoon JW; White MD; Slaughter EM; Driver JL; Khalili HS; Elliott S; Smith CD; Burow ME; Beckman BS
Cancer Biol Ther; 2011 Apr; 11(7):678-89. PubMed ID: 21307639
[TBL] [Abstract][Full Text] [Related]
14. The Role of Sphingomyelin Metabolism in the Protection of Rat Brain Microvascular Endothelial Cells by Mild Hypothermia.
Zhang HH; Wang L; Zhang W; Wan Z
Neurocrit Care; 2022 Apr; 36(2):546-559. PubMed ID: 34508278
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine 1-Phosphate Produced by Sphingosine Kinase 2 Intrinsically Controls Platelet Aggregation In Vitro and In Vivo.
Urtz N; Gaertner F; von Bruehl ML; Chandraratne S; Rahimi F; Zhang L; Orban M; Barocke V; Beil J; Schubert I; Lorenz M; Legate KR; Huwiler A; Pfeilschifter JM; Beerli C; Ledieu D; Persohn E; Billich A; Baumruker T; Mederos y Schnitzler M; Massberg S
Circ Res; 2015 Jul; 117(4):376-87. PubMed ID: 26129975
[TBL] [Abstract][Full Text] [Related]
16. Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
LeBlanc FR; Pearson JM; Tan SF; Cheon H; Xing JC; Dunton W; Feith DJ; Loughran TP
Br J Haematol; 2020 Aug; 190(3):405-417. PubMed ID: 32124438
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
18. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
19. Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.
Ding X; Zhang Y; Huang T; Xu G; Peng C; Chen G; Kong B; Friess H; Shen S; Lv Y; Roberts LR; Wang L; Zou X
Am J Cancer Res; 2019; 9(3):546-561. PubMed ID: 30949409
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells.
Schnitzer SE; Weigert A; Zhou J; Brüne B
Mol Cancer Res; 2009 Mar; 7(3):393-401. PubMed ID: 19240180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
